SCHEMBL64541

SCHEMBL64541

CN(C)C(=O)C(=O)NC12CCC(CC1)Cn1c2nc(C(=O)NCCc2ccc(F)cc2)c(O)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.46
KCNH2 Q12809 1/20 0.41
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
GPBAR1 Q8TDU6 1/20 0.34
MCHR1 Q99705 2/20 0.34
CYP2D6 P10635 1/20 0.34
CHRM1 P11229 1/20 0.34
HTR2A P28223 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
GSK3B P49841 1/20 0.33
SCD O00767 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ERCC1 P07992 1/20 0.33
FEN1 P39748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL52278 0.95 CYP2C9 (0.45) CYP2C9KCNH2MEN1KMT2AL3MBTL1
SCHEMBL63903 0.94 CYP2C9 (0.39) CYP2C9KCNH2RAB9ANPC1CYP2D6
SCHEMBL63901 0.92 CYP2C9 (0.38) CYP2C9KMT2AHSD17B10RAB9ANPC1
SCHEMBL52664 0.92 CYP2C9 (0.55) CYP2C9KCNH2MEN1KMT2AL3MBTL1
SCHEMBL64254 0.92 CYP2C9 (0.38) CYP2C9MEN1KMT2AL3MBTL1HSD17B10
SCHEMBL63523 0.91 KDM4E (0.40) CYP2C9MEN1KMT2AL3MBTL1CYP2D6
SCHEMBL64525 0.89 CA1 (0.43) CYP2C9MEN1KMT2AL3MBTL1HSD17B10
SCHEMBL9905286 0.89 CYP2C9 (0.45) CYP2C9KCNH2EGLN1
SCHEMBL63588 0.88 CYP2C9 (0.54) CYP2C9KCNH2MEN1KMT2AL3MBTL1
SCHEMBL63505 0.88 L3MBTL1 (0.39) CYP2C9L3MBTL1HSD17B10RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG CYP2C9 602/4885KCNH2 3969/4885MEN1 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.